These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Fleisher AS; Chen K; Quiroz YT; Jakimovich LJ; Gomez MG; Langois CM; Langbaum JB; Ayutyanont N; Roontiva A; Thiyyagura P; Lee W; Mo H; Lopez L; Moreno S; Acosta-Baena N; Giraldo M; Garcia G; Reiman RA; Huentelman MJ; Kosik KS; Tariot PN; Lopera F; Reiman EM Lancet Neurol; 2012 Dec; 11(12):1057-65. PubMed ID: 23137949 [TBL] [Abstract][Full Text] [Related]
9. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW; Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191 [TBL] [Abstract][Full Text] [Related]
10. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Bonfill Cosp X; Flicker L Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012216. PubMed ID: 29164603 [TBL] [Abstract][Full Text] [Related]
11. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768 [TBL] [Abstract][Full Text] [Related]
12. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Ben Bouallègue F; Mariano-Goulart D; Payoux P; Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967 [TBL] [Abstract][Full Text] [Related]
13. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy. Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833 [TBL] [Abstract][Full Text] [Related]
15. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ; Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606 [TBL] [Abstract][Full Text] [Related]
16. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O; Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640 [TBL] [Abstract][Full Text] [Related]
17. APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points. Toledo JB; Habes M; Sotiras A; Bjerke M; Fan Y; Weiner MW; Shaw LM; Davatzikos C; Trojanowski JQ; J Alzheimers Dis; 2019; 69(3):783-793. PubMed ID: 31127775 [TBL] [Abstract][Full Text] [Related]
18. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline. Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q; ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971 [TBL] [Abstract][Full Text] [Related]
19. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment. Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L; Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868 [TBL] [Abstract][Full Text] [Related]
20. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals. Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW; Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]